United States: Medical Treatment Patent Claims Held Patentable Subject Matter Under The Alice/Mayo Section 101 Test

In Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals Int'l Ltd, Slip Op. (Nos. 2016-2707, 2016-2708, April 13, 2018) the U.S. Court of Appeals for the Federal Circuit provided useful guidance for patentees seeking to survive a patent-eligibility challenge under Section 101.

In Vanda, the Federal Circuit affirmed the district court's finding that the asserted claims of U.S. Patent No. 8,586,610 ("the '610 Patent") were valid and infringed. The '610 patent relates to a method of treating schizophrenia patients with a drug called iloperidone, where the dosage range is based on the patient's genotype. The cytochrome P450 2D6 gene ("CYP2D6") encodes an enzyme known to metabolize iloperidone. The '610 Patent teaches "that treatment of a patient, who has a lower CYP2D6 activity than a normal person, with a drug [such as iloperidone] that is pre-disposed to cause QT prolongation and is metabolized by the CYP2D6 enzyme, can be accomplish[ed] more safely by administering a lower does of the drug than would be administered to a person who has normal CYP2D6 enzyme activity." '610 Patent, col. 2, ll. 15-21. QT prolongation can lead to serious cardiac issues in a patient.

The Challenged Claims and Invention

The '610 Patent is directed to treatment of patients who are poor metabolizers of CYP2D6. The claimed invention reduces the side effects associated with QT prolongation, thus enabling safer treatment of patients with schizophrenia who have this genotype. Claim 1 is representative, and reads:

"A method for treating a patient with iloperidone, wherein the patient is suffering from schizophrenia, the method comprising the steps of:

determining whether the patient is a CYP2D6 poor metabolizer by:

obtaining or having obtained a biological sample from the patient; and

performing or having performed a genotyping assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; an

if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and

if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,

wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day."

'610 Patent, col. 17, ll. 2-25.

Vanda owns a New Drug Application ("NDA") for Fanapt®, the FDA approval for which was based in part on the invention disclosed in the '610 patent.

The patent challenge arose out of defendant West-Ward's Abbreviated NDA ("ANDA") that sought approval to manufacture and sell a generic version of Fanapt®. Defendant certified in a subsequent amendment that the '610 Patent was invalid or not infringed (a similar certification was earlier made regarding a related patent but the Federal Circuit did not address that patent as no appeal from the district court's ruling related to that patent was taken). In a bench trial on Vanda's patent infringement action, the district court rejected both the jurisdictional and substantive arguments of defendant, finding the '610 Patent valid and that defendant was liable for inducing infringement. The Federal Circuit affirmed on a number of grounds, but the ruling on defendant's unsuccessful patent ineligibility argument under Section 101 patentable subject matter will be the sole focus of the balance of this post.


Defendant argued that the '610 Patent is invalid for failing to be directed to patent-eligible subject matter because the asserted claims are directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QT prolongation, and add nothing "inventive" to those natural laws and phenomena. The defendant argued that, the asserted claims here were virtually indistinguishable from those found not patentable in the U.S. Supreme Court decisions in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) and Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).

Vanda responded that the asserted claims are patent-eligible under Section 101 at both steps of the applicable two-part test.

The Federal Circuit's Analysis – The Majority View

In analyzing patent-eligibility under Section 101, the Federal Circuit cited the two-part framework established by the U.S. Supreme Court as recited in Alice Corp. Pty. v. CLS Bank Int'l, 134 S. Ct. 2347, 2355 (2014) ("Alice"). Step one of the test requires a determination "whether the claims at issue are directed to one of the patent-ineligible concepts of laws of nature, natural phenomena and abstract ideas." Slip Op. at 27-28. If the claims are found not to be directed to a patent-ineligible concept, the court need not proceed to step 2 of the analysis.

The Federal Circuit determined that the challenged claims were not directed to patent-ineligible subject matter under step 1 of the two-part Alice/Mayo test. The Federal Circuit focused on the treatment element of the claims and noted that unlike the challenged Mayo claims, the '610 Patent claims are directed to a novel treatment method. The Mayo claims, in contrast, were directed to a diagnostic method based on the "'relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of thiopurine drug will prove ineffective or cause harm.'" Slip Op. at 29. The representative Mayo claim recited:

"A method of optimizing therapeutic efficacy for treatment of an immune-medicated gastrointestinal disorder, comprising:

  1. administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and
  2. determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder,

wherein the level 6-thioguanine less than about 230 pmole per 8 X 108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and

wherein the level of 6-thioguanine greater than about 400 pmol per 8 X 108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject."

Mayo, 566 U.S. at 74-75 (quoting U.S. Patent No. 6,355,623, col. 20, ll 10-20).

Relying on its decision in Rapid Litig. Mgmt. Ltd. V. CellzDirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016), the Federal Circuit stated that "it is not enough to merely identify a patent-ineligible concept underlying the claim; we must determine whether that patent-ineligible concept is what the claim is directed to. . . If the claims are not directed to a patent-ineligible concept at step one, we need not address step two of the inquiry." Slip Op. at 28. Thus, while the '610 Patent claims did recite a law of nature, the court determined that the claims as a whole were directed to an eligible concept – treatment of a specific disease. In contrast to the Mayo claims which recited the administration of a thiopurine drug to a patient, the Federal Circuit determined that '610 Patent claims as a whole were not directed to the application of a drug to treat a disease. Slip Op. at 28-29.

The Federal court also found support in the Supreme Court's affirmation that application ineligible concepts are still patent-eligible, noting that "'[u]nlike, say a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.'" Id. In sum, the Federal Circuit characterized the '601 patented invention and claims as a treatment method and not a law of nature that is judicially excluded from patent protection.

The Federal Circuit also determined that also unlike the Mayo claims, the '610 claims are not a preemption concern, the '610 Patent claims do not tie up subsequent treatment decisions. In Mayo, the Federal Circuit stated, a doctor could violate the claim even if he did not actually alter his treatment decision and therefore, would tie up the doctor's subsequent treatment decisions whether or not the treatment does or does not change in light of the inference he has drawn using the correlations. Slip Op. at 30.

The Federal Circuit also focused on the fact that the '601 Patent claims recited particular dosage amounts, a further distinguishing fact from the Mayo claims.

Chief Judge Prost's Dissent

In Chief Judge Prost's strong dissent, he opined that the majority incorrectly relied on the claims' recitation of specific applications of the discovery underpinning the patent claims. This, he asserted, conflates the inquiry at step one with the search for the inventive concept at step two.

Chief Judge Prost also dismissed the majority's reliance on the dosage limitation of the claim by noting the Mayo claim's recitation of specific metabolite levels in the patient's blood as a comparative numerical limitation that did not rescue the Mayo claim from invalidation by the Supreme Court. Rather, he stated that similar to the Mayo claim, the '610 Patent claims are "no more than an optimization of an existing treatment of schizophrenia, just as the claims in Mayo concerned 'optimizing therapeutic efficacy' of thiopurine drugs. Mayo warned 'drafting effort[s] designed to monopolize the law of nature itself.'" Slip Op. dissent at page 5, quoting 566 U.S. at 77.

CellzDirect Still Good Law

Even though the majority and the dissent disagreed on the validity of Vanda's claims, each agreed that the court's decision in CellzDirect is consistent with its analysis and conclusion. Vanda's claims, the majority noted, are similar to the invention claimed in CellzDirect which was held patent-eligible as a new and useful method of preserving hepatocyte cells. The mere fact that the subject matter of the claims could undergo a natural process did not make the claim "directed to" that natural ability. Slip Op. at 31. "Otherwise, claims directed to actually 'treating cancer with chemotherapy' or 'treating headaches with aspirin' would be patent ineligible." Id.

The dissent did not disagree with the majority's reliance on the language and application of the Alice/Mayo two-part test in CellzDirect, but rather opined that Vanda's claim could be distinguished from the claims at issue in CellzDirect. Agreeing that CellzDirect recited a patent-eligible invention because the end result of the claims was more than the observation or detection of the ability of hepatocytes to survive multiple freeze-thaw cycles the dissent did not reach the same end result. The dissent noted that in contrast, the end result of the '610 Patent claims are no more than the conclusion of a natural law. "The fact that a reduction of iloperidone dosage in poor metabolizers ... may reduce QTc prolongation is both the means and the ends of this claim." Slip Op. dissent at 8.

Useful Guidance for Patent Drafters

The majority's opinion affirmed that method of treatment claims can be patent-eligible, even if the claim recites a natural law. Indeed, a determination that the claim as a whole at step one of the two-part eligibility test eliminates the need for an analysis to determine that the claim recites something more than the natural law itself. In addition, the majority's reliance on the dosage elements in the claims also encourages the recitation of dosage ranges in patent claims where appropriate.

Who Got it Right?

The majority and dissent each provided a reasoned and persuasive analysis. However, this author thinks that the majority got this one right. Method of treatment claims typically rely on a preliminary test or analysis of the patient. For example, one would not give a chemotherapy drug to a healthy patient. The patient must at some point have been tested and determined to been suffering from cancer and therefore be in need of such treatment. Thus, the fact that a patient had been tested prior to treatment should not prevent patenting of medical therapies. Whether the use of a chemotherapeutic the drug to treat the disease is a patentable invention is within the ambit of a prior art analysis, not patent-eligibility.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions